Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galcanezumab PK in Healthy Chinese Subjects
NCT04085289Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2019
- Primary completion
- May 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of galcanezumab in migraine (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration and Area Under the Concentration Versus Time Curve. Started Nov 2019; status: completed.
02
Drugs
galcanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04085289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04085289.